Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Person

David Meeker

Tracked across 1 events · 6 articles · First seen Apr 03, 2026 · Last active May 14, 2026

Sentiment
0
Attention
6
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
6 0
Business
Rhythm Pharmaceuticals announced that the International — European Commission has expanded the marketing authorization for Setmelanotide (setmelanotide) to treat acquired hypothalamic obesity in adults and children aged 4 years and older. This authorization follows the…
Impact: David Meeker, Chairman, President and Chief Executive Officer of Rhythm Pharmaceuticals, commented on the significance of the International — European Commission's authorization for Setmelanotide (setmelanotide) in Europe.
May 01, 2026 · 6 articles
NEWSDESK
Track David Meeker live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.